(S020) Availability of Single-Fraction Palliative Radiotherapy for Cancer Patients Receiving End-of-Life Care Within the Veterans Healthcare Administration

Publication
Article
OncologyOncology Vol 28 No 4_Suppl_1
Volume 28
Issue 4_Suppl_1

Single-fraction palliative radiotherapy for bone metastasis appears to be much more available for cancer patients receiving end-of-life care within the United Veterans Healthcare Administration when compared with the general US health care system.

Drew Moghanaki, MD, MPH, Alice Cheuk, MD, Helen Fosmire, MD, Mitchell Anscher, MD, Michael Hagan, MD, PhD, Stephe Lutz, MD, George Dawson, MD; United States Department of Veterans Affairs

Background: Recent surveys have demonstrated that < 20% of US-based radiation oncologists are willing to offer single-fraction palliative radiotherapy for bone metastasis. The United Veterans Healthcare Administration (VHA) initiated this study to determine the willingness of radiation oncologists who work within the VHA to offer single-fraction treatment.

Methods: In early 2013, a 12-question survey was emailed to all 78 radiation oncologists currently practicing at VHA radiation oncology facilities. Phone calls were made to nonresponders. Radiation oncologists who did not offer single-fraction palliative radiotherapy were evaluated by Fisher’s exact test for associations with a variety of factors.

Results: The response rate was 90% (70/78). Half were full-time employees of the VHA, and the majority had thoroughly read either the American College of Radiology (ACR) or American Society for Radiation Oncology (ASTRO) guidelines for palliative radiotherapy of bone metastases. Single-fraction palliative radiotherapy for bone metastasis is currently offered by 75.7% of respondents. Those not offering single-fraction palliative radiotherapy (24.3%) were more likely to be > 10 years out of training (37% vs 10%; P = .01) and more likely to have worked in private practice at some point in their career (36% vs 12%; P = .03). There were no associations with employment status, history of an academic appointment, or whether they had read the ACR or ASTRO guidelines.

Conclusion: Single-fraction palliative radiotherapy for bone metastasis appears to be much more available for cancer patients receiving end-of-life care within the VHA when compared with the general US health care system.

Proceedings of the 96th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(S002) Outcomes and Prognostic Factors of Stereotactic Body Radiotherapy for Soft Tissue Sarcoma Metastases
(S001) Limb-Sparing Surgery and Intraoperative Radiotherapy in the Treatment of Primary, Nonmetastatic Extremity and Limb-Girdle Soft Tissue Sarcoma
(S003) Disparities in Stage at Diagnosis and Survival in Adult Cancer Patients According to Insurance Status
(S004) Radiation Publications Underrepresented in High-Impact General Medical and Oncology Journals 
(S005) Adjuvant Radiotherapy in Stage II Endometrial Carcinoma: Is Brachytherapy Alone Sufficient for Local Control?
(S006) Extended-Field IMRT With Concomitant Boost for Node-Positive Cervical Cancer: Analysis of Regional Control Rate and Recurrence Pattern
(S007) Stereotactic Radiosurgery to the Brain With Concurrent BRAF Inhibitors for Melanoma Metastases
(S008) Use of Mobile Devices for Creation of Survivorship Care Plans
(S009) Two-Year Outcomes Following Triapine Radiochemotherapy for Cervical Cancer 
(S010) Prospective and Real-Time Data Analysis of Image-Guided Radiotherapy Across a Multinational Pediatrics Consortium: Methodology and Considerations 
(S011) Comparison of Toxicities and Outcomes for Conventional and Hypofractionated Radiation Therapy for Early Glottic Carcinoma
(S013) Adjuvant Radiation Therapy and Temozolomide for Anaplastic Gliomas: The Twelve-Year Washington University Experience
(S014) Gamma Knife Stereotactic Radiosurgery in the Treatment of Brainstem Metastases
(S015) Temporal Lobe Radionecrosis After Skull Base Radiotherapy: Dose-Volume Predictors 
(S012) Prognostic Value of Radiographic Extracapsular Extension in Locally Advanced Non-Oropharyngeal Head and Neck Squamous Cell Cancers
Recent Videos
Higher, durable rates of response to frontline therapy are needed to potentially improve long-term survival among patients with non–small cell lung cancer.
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Related Content